Introduction
Fluid biomarkers, cerebrospinal fluid (CSF) biomarkers in particular, are increasingly being used to support the clinical diagnosis of Alzheimer's disease (AD) and their utility to support the differential diagnosis of other forms of dementia and neurodegeneration has also been acknowledged 1, 2, 3, 4, 5, 6 .
Neurofilament light (NfL) is one such candidate CSF biomarker. It comprises one of 4 cytoskeletal subunits of neuronal intermediate filaments and serves to maintain the shape of nerve cells and facilitate radial axonal growth hence maintaining neuronal conduction velocity 7, 8 . Increased concentrations of NfL in the CSF are thought to reflect nerve cell damage or death 9 and have been shown to correlate with the severity of head trauma 10 , to reflect the degree of degeneration in certain dementia subtypes 11 as well as increased rates of cognitive decline and disease progression in
Alzheimer's patients 12 . Furthermore, NfL has demonstrated utility as a clinical indicator of disease severity, progression and prognosis as well as a support for patient stratification or a proxy measure of therapeutic efficacy in other neurodegenerative conditions such as multiple sclerosis (MS) 13 , amyotrophic lateral sclerosis (ALS) 14 and Parkinson's disease (PD) 11, [15] [16] [17] [18] [19] [20] .
CSF neurofilaments, similar to other CSF biomarkers, can be measured for clinical or research purposes using routine analytical platforms such as enzyme-linked immunosorbent assays (ELISAs) 18, 20 . However, for medical practitioners and researchers to recognise and accept the use of neurofilaments, and other neurodegenerative CSF biomarkers into routine diagnostic processes or clinical and research programmes, the reliability and reproducibility of their quantification needs to be established [21] [22] [23] . This is only possible by stringently validating the performance parameters of the various analytical platforms prior to using them for routine clinical or research purposes. To date attempts at investigating the performance of assays for amyloid and neurodegenerative biomarkers of AD have proven to be problematic with unacceptable levels of inter-laboratory variation being reported 24, 25 . More recently, a multicentre NfL ELISA assay validation experiment, which examined whether parameters such as pipette calibration, duration of colorimetric development or delay in analysis could contribute to the observed high levels of inter-laboratory variation reported that disparity in the accuracy of standard preparation, contributed most significantly to the observed large inter-laboratory coefficient of variation (59%) in that particular experiment 26 .
The purpose of the present work was to implement a standardised immunoassay validation protocol across multiple international research centres and in doing so determine the suitability of an established ELISA assay to quantify CSF NfL concentrations to facilitate implementation in clinical practise. Novel biomarker validation experiments comprise a subtask of the BIOMARKAPD project, a Joint Programme Neurodegenerative Disease (JPND) initiative, which seeks to optimise the performance of fluid biomarkers for the diagnosis of AD and PD. The standard operating procedures (SOPs) used in these experiments were devised specifically for the BIOMARKAPD novel biomarker assay validation project. They were designed for the partial validation of commercially available novel biomarker assays. Their purpose was to allow for easy implementation of standardised assay validation protocols and appraisal of the performance of the assay without having to assess the kits performance in relation to robustness i.e. its ability to perform despite slight methodological variation 27 .
Methods

Study design
The validation experiments were performed according to ISO/IEC 17025, ISO 5725-2, ISO 5725-4 criteria and the validation protocol was devised with reference to several supporting guidance publications [28] [29] [30] [31] [32] [33] [34] [35] . Six laboratories located in Sweden, Denmark, Germany, Norway, Finland and
Ireland took part in the study. The laboratories, with varying levels of familiarity with the assay ranging from first time to experienced users, received five UmanDiagnostics NfL ELISA kits (cat.
#10-7001, Umea, Sweden) and 20 clinical CSF samples of known NfL concentration for interlaboratory accuracy analysis. For all other validation experiments participating laboratories used locally obtained CSF samples. Each laboratory was provided with identical immunoassay validation protocol and data reporting templates. All laboratories were required to assess the UmanDiagnostics NfL ELISA kits performance with respect to six validation parameters which included an assessment of the kit's (i) sensitivity, (ii) precision (inter-and intra-assay), (iii) recovery (selectivity), (iv) linearity of dilution, (v) parallelism and (vi) inter-laboratory accuracy. Acceptable performance for each of the parameters measured was set at +/-15% of the optimum performance (100%) or a coefficient of variation (%CV) below 15% 36 .
ELISA
The NfL ELISA kits were used for quantitative determination of NfL in human CSF samples.
ELISAs were performed according to the manufacturer's instructions and as described before 18, 26 .
In brief, standards (lyophilised bovine NfL spinal cord concentrate -TBC) were re-suspended in sample diluent to give a top concentration of 10,000pg/mL. The top standard was vortexed briefly and kept at room temperature (RT). The remaining standards were prepared from serial dilutions of the top standard and are summarised in Table 1 . Initially plates were washed (x3) with wash buffer (300μL), they were then flipped over and wash buffer residues removed by tapping the plate against blotting paper. Next 100μL of standard or sample were added to each well according to the experimental templates and incubated for 1hr at RT (20-25 0 C) with agitation (800rpm). Subsequently, plates were washed (x3) as described above and 100μL of freshly diluted tracer (biotin labelled antiNfL mAb) was added to each well and incubated for 45min at RT (20-25 0 C) with agitation (800rpm). Again, plates were washed (x3) and 100μL of newly diluted conjugate (streptavidin-HRP) was added to each well and incubated for 30min at RT (20-25 0 C) with agitation (800rpm). Next, plates were washed (x3) and 100μL of TMB was added to each well and incubated for 15min at RT (20-25 0 C) with agitation (800rpm). Finally, 50μL of stop solution was added to each well and the absorbance read at 450 nm.
Sensitivity
The sensitivity of the assay was determined by running 16 blank samples (sample diluents). Mean and standard deviations (SDs) of the blanks were calculated and the lower limit of detection (LLOD) was calculated based on a signal of 10 SDs above the mean of the blanks.
Precision
To assess the precision of the assay, five quality control (QC) samples with pre-defined low and high NfL content within the linear range of the standard curve were collected by each laboratory. The samples were divided into 24 aliquots and stored at -80 o C until needed. For the intra-assay precision 12 replicates of each QC sample were run on day one. For the inter-assay precision three replicates of the samples were run on days two through five. The mean, SDs and %CV were calculated for repeatability (inter-assay) and intermediate precision (intra-assay).
Recovery
Recovery (selectivity) was assessed over two days. Five CSF samples of known low NfL content were used in these experiments. On both days the samples (three samples day one; two samples day two) were diluted 1:1 as per assay requirements and divided into four aliquots. Three of the aliquots were spiked with calibrator stock solution to low, medium and high NfL concentrations on the linear range of the standard curve. Samples were spiked with 5% volume to 95% volume of the diluted sample. The fourth aliquot was spiked with an equal volume of the sample diluent (neat sample).
Recovery was calculated according to the following formula: 
Linearity of dilution
To assess the linearity of dilution three pre-selected undiluted CSF samples with known high concentrations of NfL were selected and spiked with calibrator stock solution to a concentration beyond the upper limit of detection (ULOD) of the assay (10µg/mL). Serial dilutions of each spiked sample were carried out until the concentration was below the lower limit of detection (LLOD).
Linearity of dilution was calculated according to the following formula: 
Data analysis
All data analysis was performed by the project coordinating site to ensure uniformity of results.
Standardised project reporting templates were used to calculate the results were applicable. Data was analysed using Excel (Microsoft, Version 2010) and GraphPad (GraphPad Software Inc, Version 5.0, La Jolla, CA, USA) was used to create figures.
Results
Sensitivity
The mean LLOD reported by the six laboratories based on the 16 blank samples was 57.5 pg/ml and ranged from 23.3 pg/ml to 100 pg/ml ( Table 2 ). The manufacturer's reported LLOD is 32 pg/ml.
Precision
The average intra-assay CV based on the calculated NfL concentrations was 3.7% and ranged from 1.7 to 7.1% (Figure 1a) . The average inter-assay CV for the low NfL content samples was 13.2%
(range 4.0 to 21.1%), for medium NfL content samples 12.4% (5.9 to 18.1%) and for the high NfL content samples 15% (9.8 to 21.2%) resulting in an average inter-assay CV of 13.5% for all samples (Figure 1b) .
Recovery (selectivity)
The reported recovery percentages were, in most cases outside the pre-defined range of 85-115%.
Only samples spiked to medium NfL content in Lab #1 and #2 and to high NfL content in Lab #2
were within the pre-defined range (Table 3) .
Linearity of dilution
The data showed that 30% of all dilutions did not fall within the pre-defined range of 85%-115% (Figure 2 ).
Parallelism
Two of the 6 participating laboratories (Lab #2 and #5) reported parallelism within the pre-defined range of 85-115% (Figure 3 ).
Inter-laboratory precision
The inter-laboratory accuracy of the measurements of NfL concentrations was assessed with 20 CSF patient samples distributed between six laboratories. The inter-laboratory CV for all samples was 27%
(range 16% to 32%) and was outside the pre-defined level of 15% (Figure 4) . The data showed that samples with the highest NfL content had the lowest %CV (Figure 4a ).
The differences in the standard curve OD values reported by the centres do not explain the high interlaboratory %CV of the samples (Figure 4b ). For instance, difference in the OD values of the standard curve between Lab #3 and Lab#5 is on average 29% but the average difference in the calculated NfL concentrations is 14%. However, in another example, the difference in the OD values of the standard curve between Lab #1 and Lab #5 was 7% but the average difference of calculated NfL concentrations was 25%.
In order to elucidate possible sources of variation which might account for the high inter-laboratory %CV the participating laboratories were asked to complete a questionnaire (adapted from Petzold et al., 2010) regarding the sample and kit handling conditions during the series of experiments.
In brief, variation was found in the sample storage conditions and time taken to incubate the standards and samples following reconstitution of the calibrator (15-60min), minor variations in the time allowed for the colour reaction and whether plates were protected from sunlight were also observed.
No difference was observed with respect to ELISA kit storage conditions, the temperatures at which the assays were executed and plate agitation details. In two of six cases pipettes were calibrated prior to the validation experiments. The 20 inter-laboratory patient CSF samples used by 5 of the 6 laboratories underwent two shipments on dry ice with the exception of those used by the co-ordinating site. The assay data was calculated using the 4 parameter logistic (4PL) nonlinear regression model by all six laboratories (Table 4) .
Discussion
The data showed that the assay has good sensitivity with an average LLOD reported by the participating laboratories of 57.5 pg/ml. Assay precision, as assessed by measuring inter-and intraassay CV was good at 13.2% and 3.7% respectively. Importantly however, it must be noted that that maximal spiking using assay calibrator, particularly in the recovery and linearity of dilution experiments was not, in most cases, achieved. This is due to the fact that the lyophilised calibrator is pre-diluted 1:1 by the manufacturer to allow for the 1:1 dilution of the samples in accordance with the NfL ELISA assay protocol thus, once re-suspended in diluent, the true concentration of the calibrator is in reality half of what is assumed. This pre-dilution of the calibrator was accounted for during calculations by the data coordinating site so that the data reflected 'true' calibrator concentrations.
Recovery (selectivity)
Recovery was assessed by measuring non-native NfL in the presence of endogenous CSF matrix, selectivity of the assay in the six laboratories was for the most part outside the pre-defined range of 85-115%. Usually poor recovery points to interference in sample measurement by components in the matrix, such as blood contamination, which may affect antibody binding 37 and is usually resolved by the addition of additional assay diluent to samples 27 . However, in this instance confounding elements such as the blood contamination status of the samples was unknown, this fact, in combination with the calibrator concentration miscalculation means that the recovery data must be interpreted with caution.
However, if the assay were to display poor selectivity the observed values would tend to deviate in one direction, that is, either positive or negative. However, the results reported in this experiment showed that the data seemed to deviate in both directions suggesting that factors, other than those traditionally thought to affect selectivity, contributed to the poor recovery. Thus in the absence of a matrix effect it must be considered that recovery may have been hampered by the use of non-native (bovine) NfL calibrator protein to spike the CSF samples which might behave differently than native (human) NfL protein in the CSF 37 .
Linearity of dilution It is important to be able to demonstrate that if the concentration of a protein of interest is above the ULOQ of an assay that it can be diluted, without affecting accuracy of measurement, to a concentration within the working range of the assay 34 . Linearity of dilution was suboptimal in these experiments as 30% of dilutions were outside the pre-defined acceptance range. Similar to the recovery experiments poor linearity of dilution can imply that the sample matrix and assay diluent affect analyte detection differently 27 but, again, it is difficult to assess the validity of these results due to the assumed starting concentration of the calibrator being incorrect. Consequently only two-or three-fold dilutions of samples were made in these experiments before the LLOD was reached when normally four or five-fold dilutions would be compared. The 'hook effect' can also be discounted as an influencing factor in this experiment. The 'hook effect' is observed when the analyte in question is in very high concentrations beyond the theoretical upper limit of detection of the assay and can result in artificially low concentrations of analyte being reported 38 . However this phenomenon was not observed in these experiments as, again, the working concentration of the calibrator used for spiking was significantly lower than originally assumed.
Parallelism
We examined parallelism comparing standard bovine NfL in assay diluent and endogenous NfL in CSF. Antibody affinity was investigated by comparing the slopes for the native NfL in CSF versus the calibrator protein in assay diluent. As two of six centres observed a parallel relationship between their samples and the calibrator sample we cannot conclude that the antibodies used in the assay have poor affinity.
A failure to observe parallelism could point to poor robustness in this particular experiment; however this can only be established by a more in-depth systematic examination of critical factors such as preanalytical variables pertinent to this validation parameter 28 . Alternatively, failure to observe parallelism, and indeed some of the other validation parameters, could be in part due to some of the less practiced operators experiencing difficulty with interpretation or complexity of the plate plans and SOPs. It has been argued that as NfL has the tendency to re-aggregate following suspension [39] [40] [41] [42] that delays in sample and standard incubation could account for the failure to satisfactorily measure NfL in many experiments 26 . The data show that between 15 and 60 minutes were taken, from the time standards were reconstituted, to incubate the standards and samples on the ELISA plates. The observed delay could be in part due to a lack of operator familiarity with the assay protocol or project SOPs. On foot of this observation we recommend that for validation experiments the operator use both vials of standard stock solution supplied in the kits to prepare the standard curve and spike samples as promptly as practicable. By using both vials during the course of the validation time to incubation of standards and samples would be significantly cut, diminishing the possibility of NfL protein aggregation and/or degradation contributing to variation in the performance of this assay across sites. Furthermore, future validation projects could be further optimised by adopting alternative assay validation SOPs such as those recently published by BIOMARKAPD 43 which are designed to allow for the inexperienced operator.
Inter-laboratory precision The inter-laboratory CV at 27% is poor but cannot, as in other assay validation experiments be attributed to lot to lot variation in the kits 44 as all centres taking part worked with kits from the same lot. Nonetheless, despite the variation the data do point to the positive effects of implementation of a standardised protocol in that no one laboratory reported consistently high or low values and discrepancies seem to be spread out among the laboratories. In support of the positive effect of implementation of validation protocols a previous multi-centre study, albeit with greater numbers of participating laboratories, which did not use standardised protocols in the validation of the UmanDiagnostics NfL ELISA reported a significantly higher inter-laboratory precision CV of 59% 26 .
In agreement with our observations, Petzold and colleagues also observed variations in the concentration of standards and their associated optical densities (OD) 26 . They noted that nonsystematic error due to variations in the preparation of standards could be responsible for up to twofold differences in sample concentration, and identified differences in the accuracy and types of pipettes used to make the standards and dispense samples as possible sources of variation. Our own data indicates that four of the six centres reported not calibrating their pipettes prior to the validation experiments and declared using different pipettes for the preparation of the assay standards as to those used for pipetting samples. However, given the available data we are unable to definitively identify a reason for the inter-laboratory variation and further studies examining pre-analytical variation within the context of using standardised SOPs in a multi-centre context should be conducted.
Limitations and recommendations A regularised approach to assay performance is required to ensure the validity of intra-and inter- Nonetheless given the data we conclude that the UmanDiagnostics ELISA kit for detection of human NfL is suitable for routine NfL quantification. However, we caution against comparing patient data sourced from different centres until the reasons for the high inter-laboratory CV are identified. We also recommend that going forward SOPs which minimise procedural complexity and allow for operator naïveté should be considered for future multi-centre validation studies. Table 3 . The NfL Elisa assay used in the study had low selectivity and specificity. The selectivity of the assay was assessed using recovery experiments with three CSF samples with known low NfL content and spiked to low, medium and high NfL concentration with calibrator. The reported recovery percentages were, in most cases, either below or above the pre-defined range of 85-115%. Lab#1 51%/24% 31%/32% 24%/47% 7%/25% 24%/22% 
